Sector News

Reuters: Rare disease drugmaker PTC Therapeutics explores sale – sources

February 25, 2015
Life sciences
(Reuters) – Rare disease drugmaker PTC Therapeutics Inc (PTCT.O) is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc (SHP.L) and BioMarin Pharmaceutical Inc (BMRN.O), according to people familiar with the matter.
 
The company, which treats a muscle-wasting disorder known as Duchenne, is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private.
 
Representatives for South Plainfield, New Jersey-based PTC Therapeutics could not be reached for comment. Representatives for Shire and BioMarin declined to comment.
 
The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to $68.44 on reports of the potential sale, before easing to $63.51, up 15.1 percent.
 
Makers of treatments for rare diseases, also known as orphans, are attractive acquisitions for large pharmaceutical companies looking to offset a drop in sales as patents on their blockbuster products expire.
 
Prosena Holding NV, which also makes a treatment for Duchenne, was acquired last November by BioMarin for $840 million.
 
PTC Therapeutics’ drug Translarna has received orphan drug status in the European Union and the United States and is in process of seeking U.S. Food and Drug Administration approval.
 
Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.
 
Shire has made several acquisitions to bolster its focus on rare diseases, including a $5.2 billion purchase of NPS Pharmaceuticals in January and a $4.2 billion deal for ViroPharma last year.
 
It also took a look at acquiring Salix Pharmaceuticals Ltd (SLXP.O) in recent weeks but ended up passing on the deal, according to sources.
 
(Reporting by Olivia Oran and Soyoung Kim in New York; Editing by Christian Plumb and Jeffrey Benkoe)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend